Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis
Clinical trial NCT04735432 · COMPLETED
Trial details
- NCT number
- NCT04735432
- Sponsor
- argenx
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-05
- Primary completion
- 2021-11-02
- Enrollment
- 110
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.